Diabetic retinopathy steals sight slowly. It begins with damage so subtle that patients don't notice anything wrong, progresses through stages of worsening vision, and can end in complete blindness. It affects roughly one-third of all people with diabetes — more than 100 million worldwide — and until now, treatment has been limited to managing damage that has already occurred.

A study published this week may have just changed that equation. Researchers at University College London have identified a single protein, called LRG1, that triggers the very first stage of damage in diabetic retinopathy. And in mouse models, blocking that protein stopped the disease before it could begin.

## Finding the Trigger

Diabetic retinopathy has long been understood as a vascular disease — it damages the tiny blood vessels in the retina, the light-sensitive tissue at the back of the eye. But the precise mechanism that initiates this damage has been elusive.

The UCL team, led by Professor John Greenwood, discovered that LRG1 acts on the smallest blood vessels in the retina, called capillaries, causing them to constrict. This constriction reduces blood flow and oxygen supply to the retinal tissue, triggering a cascade of damage that eventually leads to the hallmark features of diabetic retinopathy: leaking blood vessels, swelling, and the growth of abnormal new vessels.

"We've been treating the consequences of this disease for years," said Professor Greenwood. "Now we've found what starts it. That's a fundamentally different thing."

## The Mouse Model Results

To test their theory, the team developed a method to block LRG1 in diabetic mice. The results were dramatic. Mice with blocked LRG1 showed no early retinal damage, while control mice developed the expected pattern of vascular constriction and oxygen deprivation.

The treated mice maintained normal retinal blood flow, normal oxygen levels, and normal visual function. The disease simply didn't develop.

"It was one of those moments in the lab where everyone just stopped and stared at the data," recalled Dr. Athina Dritsoula, the study's lead author. "We expected improvement. We got prevention."

## Why This Matters

The implications are significant for several reasons. First, diabetic retinopathy is currently the leading cause of blindness in working-age adults in developed countries. Existing treatments — laser therapy and injections into the eye — can slow progression but cannot reverse damage and are invasive and uncomfortable for patients.

Second, the protein LRG1 can potentially be detected through a simple blood test, meaning it could serve as an early warning biomarker long before patients notice any visual symptoms.

Third, blocking a single protein is a pharmacologically tractable target. Antibody therapies that neutralize specific proteins are well-established in medicine, meaning the path from this discovery to a potential treatment is clearer than it might be for more complex biological mechanisms.

## The Human Timeline

The team is now working with pharmaceutical partners to develop an LRG1-blocking therapy for human trials. Professor Greenwood estimated that clinical trials could begin within two to three years, with a focus initially on patients with early-stage diabetic retinopathy who have the most to gain from a preventive approach.

"What excites me most is the word 'prevention,'" he said. "We're not talking about treating blindness. We're talking about preventing it. For millions of people living with diabetes, that distinction is everything."

For the global diabetes community, which has long watched helplessly as retinopathy claimed the vision of friends and family members, this discovery offers something that has been in short supply: a reason to believe the fight can be won before the damage is done.